Radioactive tracer could spot hidden cancers in ovarian, lung, and pancreatic tumors

NCT ID NCT06843629

Diagnosis Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new radioactive imaging agent that targets a protein called MSLN, found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage ovarian cancer, lung adenocarcinoma, and pancreatic cancer in 100 patients and healthy volunteers. The goal is to improve diagnosis and help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: [68Ga]Ga-NOTA-MSLN antibody fragment (a radioactive imaging agent)
What this could lead to: If successful, this could provide a more accurate way to detect and stage certain cancers, helping doctors choose the best treatment.
What could go wrong: This is an early-phase diagnostic study, not a treatment. The imaging agent may not prove more effective than current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with clinically suspected or confirmed malignant tumors such as pancreatic cancer, ovarian cancer, or lung adenocarcinoma (supporting evidence includes serum-related tumor markers, imaging data such as ultrasound, CT, MRI, etc., and histological pathology examination, etc.) who are in good general condition.

Ages: 18 to 65 years
Sex: Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Each subject must meet all enrollment criteria to be eligible to participate in the study: 1. The subject or his/her legal representative is able to sign and date the informed consent form; 2. A commitment to comply with the research procedures and to cooperate in the implementation of the full research process; 3. Adult patients or healthy volunteers (aged 18 or above) of either sex; 4. Patients with clinically suspected or confirmed malignant tumors such as pancreatic cancer, ovarian cancer, or lung adenocarcinoma (supporting evidence includes serum-related tumor markers, imaging data such as ultrasound, CT, MRI, etc., and histological pathology examination, etc.) and in good general condition; 5. Consistent with the results of specific laboratory tests; 6. Females of childbearing potential who have been using contraception for at least one month prior to screening and who are committed to using contraception for the entire study period and until a specified time after the end of the study； 7. Other set entry criteria. Exclusion Criteria: * All subjects who meet any of the exclusion criteria baseline will be excluded from the study: 1. Those who are unable to complete a PET/MR or PET/CT examination (including inability to lie down, claustrophobia, radiophobia, etc.); 2. Having other comorbidities; 3. Patients with known hypersensitivity to MSLN antibody fragment developers or synthetic excipients; fasting blood glucose level greater than 11.0 mmol/L prior to 18F-FDG injection； 4. Have a history of comorbid drug use; 5. Patients considered by the investigator to have poor compliance; 6. Patients during pregnancy or lactation; 7. Persons with other factors that make participation in this test inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung exocrine pancreatic carcinoma lung adenocarcinoma malignant pancreatic neoplasm ovarian cancer pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung adenocarcinoma Ovarian cancer Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Radioactive tracer could spot hidden cancers in ovarian, lung, and pancreatic tumors

What the study statuses mean